WO2008004190A2

WO2008004190A2 - Polymorphic form of duloxetine hydrochloride

Info

Publication number: WO2008004190A2
Application number: PCT/IB2007/052603
Authority: WO
Inventors: Sujoy Biswas; Keya Karanjai
Original assignee: Ranbaxy Laboratories Ltd
Current assignee: Ranbaxy Laboratories Ltd
Priority date: 2006-07-03
Filing date: 2007-07-03
Publication date: 2008-01-10
Anticipated expiration: 2009-01-03
Also published as: CA2656126A1; US20100261775A1; EP2040697A2; CN101522189A; WO2008004190A3

Abstract

The present invention relates to Form I of duloxetine hydrochloride and its preparation.

Description

Field of the Invention

The present invention relates Io a polymorphic form of dufoxetine hydrochloride and processes for its preparation. The polymorphic form of the current invention is designated Form I. The present invention also relates to a process for preparing duloxelinε hydrochloride from duloxetine maleate.

Background of the Invention

Duloxetine hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. It is chemically (^■f-)-(5')-Λ^r-methyl-γ-(l- naphthyloxy)-2-thioρhεnepropyl amine hydrochloride as represented by Formula I:

U.S. Patent No 5,023,269 provides a process for the preparation of raceraic duloxetine oxalate and it discloses maleate and oxalate salts of S-(+)-duk>xetinε. However, the '269 patent does not provide any method to separate specific enantiomers of duloxetine. US Patent No 5,491,243 provides a similar process for preparing for duloxetine, wherein the final compound of duloxetine is isolated as a hydrochloride salt using ethyl acetate as a solvent and seeding. The '243 patent says that the desired product is prepared in yields in the range of 95% with very little racemization and that previous procedures gave a product of inferior purity.

PCT application WO 05/019199 provides processes for preparing amorphous duloxetine hydrochloride by vacuum drying methods. WO 05/108386 provides processes for preparing Forms A, B and C of tree base of duloxetine. Various processes for the preparation of duloxetine and its intermediates are also provided in EP 0,457,559 A3, US 5,362,886, WO 03/062219, WG 03/070720, EP 1,506,965, WO 04/005307, US 2004/0181058, WO 04/056795, WO 04/065376, WO 04/055194, WO 03/018572, JP 2003492681 A2, US 2003/225153, US 2005/107621 , WO 04/005220, WO 04/005239, WO 04/011452, WO 04/013123, WO 04/016603, DE 10237272 Al ₅ WO 04/020389, WO 04/024708, WO 04/031 168, EP 1411045 Al, DE 10248479 Al , DE 10248480 Al, WO 04/090094, WO 04/103990, WO 05/021527, WO 05/033094, WO 05/073215, WO 05/080370, US 2003/225274, US 2003/225153, US 2004/023348, US 2004/023344, US 6,924,386, DE 10237272 Al , US 2004/181058. Brief Description of the Figures

Figure 1 is an X-ray powder diffraetogram (XRPD) pattern of Form I of duloxetine hydrochloride.

Figure 2 is a Fourier-Transform Infra-red (FTIR) spectrum of Form S of duloxetine hydrochloride. Summary of the invention

The present invention provides duloxetine hydrochloride Form I, which is suitable for preparing pharmaceutical dosage forms. The present invention further provides a process for preparing Form 1 of duloxetine hydrochloride. The present inventors have also developed a simple and efficient process for preparing duloxetine hydrochloride from duloxetine maleate,

In one aspect, Form I of duloxetine hydrochloride is provided, having, for example, XRPD pattern substantially as provided, for example, in Figure i. The XRPD pattern of Form I of duloxetine hydrochloride can be characterized by peaks at 2Θ values 9.74, 14.02, 18.20, 18.86, 19.02. 21.00, 22.28, 23.28, 23,48 and 24.64+0.2. It is further characterized by additional peaks at 2Θ values at 14.62, 16.14, 19.36, 19.64, 20.16, 21.46, 21.72, 22.74, 25.72, 26,16, 26.58, 27.52, 28.08, 29.1, 29.36 and 30.5±0.2. A representative FTIR spectrum of Form I of duloxetine hydrochloride is provided in Figure 2. In another aspect, a process for the direct preparation of duloxetiae hydrochloride from duloxetine maieate without the need for seeding is provided, wherein the process comprises, a) treating duloxetine maieate with a base to obtain free base of duloxetine, b) contacting the free base of duloxetine with hydrochloric acid, and c) isolating duloxetine hydrochloride from the reaction mixture.

The duloxetine maieate can be prepared, for example, according to the method provided in Tetrahedron Letters 1990, 31(49), 7101-7104, The maieate salt of duloxetine is treated with a base in the presence of water or water miscible organic solvent, or a mixture thereof. An alkali metal hydroxide is preferably used as the base. The liberated free base of duloxetine is extracted with a water immiscible organic solvent. The water immiscible organic solvent is preferably an aromatic hydrocarbon. According to the processes described herein, the free base of duloxetine is not required to be isolated from the organic solvent and it is contacted with hydrochloric acid after partially concentrating the solution. Hydrochloric acid may be used as a gas or as a solution in water or organic solvents. The duloxetine hydrochloride may be isolated from the reaction mixture by solvent precipitation, concentration, distillation and other such conventional techniques.

In yet another aspect, a process for the preparation of Form I of duloxetine hydrochloride is provided, wherein the process comprises, a) dissolving duloxetine hydrochloride in a solvent, b) treating the solution obtained in step (a) with an anti-solvent, and c) isolating Form I of duloxetine hydrochloride from the reaction mixture.

Duloxetine hydrochloride-m any previously known crystalline or amorphous form-prepared by methods known in the art can be used as the starting material. Duloxetine hydrochloride can be dissolved in an organic solvent or a mixture of an organic solvent and water. The organic solvent can be, for example, a C_1-3 alkanol, acetonitrile, acetone, dioxane, dimethyl formarnide or tetrahydrofuran. The organic solvent can be, tor example, absolute ethanol. The duloxetine hydrochloride can be dissolved by heating the mixture from about 4O⁰C to about 8O⁰C. An anti-solvent may be added to the solution so obtained. The anti-solvent can be, for example, an aliphatic ether, aliphatic hydrocarbon, aromatic hydrocarbon or aliphatic ester. The reaction mixture can be initially heated to a temperature of about SO⁰C and then cooled to 35⁰C or below to obtain Form I of duloxetine hydrochloride.

In still another aspect, a pharmaceutical composition comprising Form I of duloxetine hydrochloride is provided which optionally contains one or more excipients. In yet a further aspect, a method for inhibiting serotonin uptake in mammals is provided which comprises administering a pharmaceutically effective amount of Form 1 of duloxetine hydrochloride to a mammal in need of treatment with a serotonin uptake inhibitor.

Powder XRD of the samples were determined by using X-Ray difrractorneier, Sligaku Corporation, RU-H3R, Goniometer CN2155 A3, X-Ray tube with Cu target anode. Power: 40 KV, 100 raA, Scanning speed: 2 deg/min step: 0.02 deg, Wave length: 1.5406

A

FTIR spectra of the samples were recorded on a Perkin-Elmeri 6 PC instrument, as potassium bromide pellets. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

a) Preparation of duloxεtine:

A suspension of duloxetine maleate (20 g) in water was basified to about pϊ-1 12 using 30% aqueous sodium hydroxide solution at about 25⁰C. The reaction mixture was extracted with toluene (2 x 200 mL), The toluene layer was washed with water till the pM was between 7 and 8 and then concentrated under reduced pressure to obtain the title compound as an oily mass which was used directly in the following step.

The oily mass obtained in step (a) was dissolved in ethyl acetate (90 mL). The pH of the solution was adjusted to between 1,5 and 2,0 using a solution of hydrochloric acid in ethyl acetate [Assay -8% (w/w)] at 5-10⁰C to attain the pH of 1.5 to 2.0. The reaction mixture was stirred at 5°-10⁰C for 2 h. The resultant solid was filtered, washed with ethyl acetate (2 x 20 rnL) and dried under vacuum at 45°~50°C for 8-10 h to obtain the title compound as an off-white solid.

Yield: 14 g

A mixture of duloxεtine hydrochloride obtained as prepared in Example 1 (10 g) in absolute ethanol (30 mL) was stirred ai ό5°-70°C for 15 minutes to obtain a clear solution. Activated charcoal (1.0 g) was added to the solution so obtained and stirred at 65°-70°C for further 30 minutes. The charcoal was filtered and washed with absolute ethanol (3 x 15 mL) at about 25⁰C. Diisopropyl ether was added (35 mL) to the combined filtrate and washed at 40°-45°C. The reaction mixture was reheated to 65°-68°C for 15 minutes and cooled to 25°~30°C to obtain a white solid as a precipitate. The mixture was stirred at 25"- 3O⁰C for 2 h and further at 5°-10°C for 2 h. The solid was filtered, washed with a mixture of absolute ethanol (7.5 mL) and diisopropyl ether (7.5 mL) at about 25⁰C and dried under vacuum at 45°-50°C for 8 to 10 h to obtain the title compound having XRPD and FTIR patterns as depicted in Figures 1 and 2 respectively.

Yield: 7.5 g

Enantiomeric purity: 99.99%.

Claims

We Claim: 1. Form I of duloxetine hydrochloride having an XRPD pattern substantially as depicted in Figure 1.

2. Form ϊ of duloxetine hydrochloride having peaks at substantially the following 2Θ values in the XRPD plot: 9.74, 14.02, 18.20, 18.86, 19.02, 21.00, 22.28, 23.28, 23.48, and 24.64 ± 0.2.

3. Form ϊ of duloxetine hydrochloride having substantially an FTIR spectrum as depicted in Figure 2.

4. A process for the preparation of Form I of duloxetine hydrochloride, comprising: a) dissolving duloxεtine hydrochloride in a solvent; b) treating the solution obtained in step (a) with an anti-solvent; and c) isolating Form I of duloxetine hydrochloride from the reaction mixture.

5. A process according to claim 4, wherein the solvent is at least one of a C₁^ alkanol, acetomtrile, acetone, dioxane, dimethyl formamide or tetrahydrofuran. 6, A process according to claim 5, wherein the solvent is absolute ethanol. 7. A process according to claim 4, wherein the anti-solvent is at least one of an aliphatic ether, aliphatic hydrocarbon, aromatic hydrocarbon or aliphatic esler. 8, A pharmaceutical composition comprising Form I of duloxetine hydrochloride. 9. A method for inhibiting serotonin uptake in mammals which comprises administering a pharmaceutically effective amount of Form I of duloxetine hydrochloride to a mammal in need of treatment with a serotonin uptake inhibitor. 10. A process for the preparation of duloxetine hydrochloride, comprising: a) treating duloxetine nialeate with a base to obtain free base of duloxetine; b) contacting the free base of duloxetine with hydrochloric, acid; and c) isolating duloxetine hydrochloride from the reaction mixture, without using any seed, 11. A process according to claim 5, wherein the base is an alkali metal hydroxide. 12. A process according to claim 5, wherein step a) is carried out in the presence of water or water miscible organic solvent, or a mixture thereof. Λ process according to claim 7, wherein step a) further comprises extracting the free base of duloxetine with a water immiscible organic solvent.